Product
  • Product
  • Supplier
  • Inquiry
    Home >

    News

    >

    AstraZeneca

    Articles Related to AstraZeneca
    AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn

    AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn

    In addition to Synagis, the deal also means that Sobi will receive 50% of all future earnings of candidate drug MEDI8897, a follow-on ca...
    lung-drug AstraZeneca

    2018-11-14

    AstraZeneca Expands Global Medicines Development Centre in Bengaluru

    AstraZeneca Expands Global Medicines Development Centre in Bengaluru

    Globally, GMD works with AstraZeneca’s two biotech units – Innovative Medicines and Early Development (IMED) and MedImmune – and the Glo...
    AstraZeneca Medicine

    2018-06-21

    AstraZeneca Expands Global Medicines Development Centre in Bengaluru

    AstraZeneca Expands Global Medicines Development Centre in Bengaluru

    Globally, GMD works with AstraZeneca’s two biotech units – Innovative Medicines and Early Development (IMED) and MedImmune – and the Glo...
    AstraZeneca Medicine

    2018-06-15

    AstraZeneca to Invest $90-Mn in India over Next 5 Years

    AstraZeneca to Invest $90-Mn in India over Next 5 Years

    Biopharmaceutical firm AstraZeneca has revealed plans to invest $90-mn (around Rs. 590-crore) in India over the next five years. The announcement followed the signing of a bilateral innovation partnership for a sustainable future between Sweden and India.
    Ionis Pharma, Astrazeneca to Advance New Drug for Nash

    Ionis Pharma, Astrazeneca to Advance New Drug for Nash

    US-based Ionis Pharmaceuticals, the leader in antisense therapeutics, recently announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca following advancement of the drug into development.
    AstraZeneca Ionis Pharma

    2018-04-12

    Astrazeneca’s Lokelma Receives EU Approval

    Astrazeneca’s Lokelma Receives EU Approval

    AstraZeneca is a global, science-led biopharmaceutical company, announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults with hyperkalaemia.
    • 1
    • Go to Page Go
    Suggestions
    Email:
    Message:
    Send Message